Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has taken a significant step toward expanding its oncology portfolio by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is the first step toward negotiating a definitive agreement that would grant Onco an exclusive option on Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3). This move signals a strategic pivot toward next-generation cancer immunotherapy, combining oral small-molecule checkpoint inhibition with Onco's existing expertise in DNA damage response (DDR) therapeutics.
The proposed collaboration aims to merge Ifowonco's oral small-molecule immune checkpoint technology with Onco-Innovations' strengths in translational oncology and clinical development. The companies believe that combining DDR inhibition with LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. This approach is particularly notable because currently approved LAG-3 therapies are monoclonal antibodies administered intravenously, whereas Ifowonco's program focuses on developing orally available small-molecule inhibitors. Oral administration offers potential advantages in patient convenience, dosing flexibility, and the ability to combine with other oral agents.
The companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its potential use alongside DDR-based therapeutic approaches, including Onco-Innovations' ONC010 program. This could create a synergistic effect, as DDR inhibition may sensitize tumour cells to immune attack, while LAG-3 blockade could reinvigorate exhausted T cells. If successful, this combination could address a significant unmet need in solid tumours that are resistant to current immunotherapies.
Thomas O'Shaughnessy, CEO of Onco-Innovations, commented on the potential agreement, stating that it could position the company "at the intersection of precision oncology and next-generation cancer immunotherapy." This statement underscores the strategic importance of the deal, which could diversify Onco's pipeline and strengthen its competitive position in the rapidly evolving field of cancer immunotherapy.
The LOI is non-binding, meaning that the terms are not final, and a definitive agreement is subject to negotiation. However, the announcement demonstrates Onco's commitment to expanding its therapeutic arsenal beyond its current focus on DDR-based treatments. The company has already secured an exclusive worldwide license to patented technology targeting solid tumours, and this new initiative could complement its existing portfolio.
Investors and industry observers will be watching closely as the negotiations progress. If a definitive agreement is reached, it could mark a significant milestone for Onco-Innovations, potentially accelerating its development timeline and broadening its clinical applications. For more information on Onco-Innovations, visit the company's newsroom at https://ibn.fm/ONNVF.
